Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea (aflibercept), was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
Reuters Health Information